Muscle microRNAs in the cerebrospinal fluid predict clinical response to nusinersen therapy in type II and type III spinal muscular atrophy patients.

MLA

Magen, Iddo, et al. “Muscle MicroRNAs in the Cerebrospinal Fluid Predict Clinical Response to Nusinersen Therapy in Type II and Type III Spinal Muscular Atrophy Patients.” European Journal of Neurology, vol. 29, no. 8, Aug. 2022, pp. 2420–30. EBSCOhost, https://doi.org/10.1111/ene.15382.

APA

Magen, I., Aharoni, S., Yacovzada, N. S., Tokatly Latzer, I., Alves, C. R. R., Sagi, L., Fattal, V. A., Swoboda, K. J., Katz, J., Bruckheimer, E., Nevo, Y., & Hornstein, E. (2022). Muscle microRNAs in the cerebrospinal fluid predict clinical response to nusinersen therapy in type II and type III spinal muscular atrophy patients. European Journal of Neurology, 29(8), 2420–2430. https://doi.org/10.1111/ene.15382

Chicago

Magen, Iddo, Sharon Aharoni, Nancy Sarah Yacovzada, Itay Tokatly Latzer, Christiano R. R. Alves, Liora Sagi, Valevski, Aviva Fattal, et al. 2022. “Muscle MicroRNAs in the Cerebrospinal Fluid Predict Clinical Response to Nusinersen Therapy in Type II and Type III Spinal Muscular Atrophy Patients.” European Journal of Neurology 29 (8): 2420–30. doi:10.1111/ene.15382.